A method for quantitative analysis of plasma concentration of new compound wsj-557 in SD rat plasma

Abstract

The invention relates to a quantitative analysis method of the plasma-drug concentration of a novel compound WSJ-557 in SD rat plasma. The method comprises the following steps of (1) adding methanol and internal standard working fluid into the SD rat plasma after the WSJ-557 intragastric administration; after the vortex, adding ethyl acetate for liquid-liquid extraction; then, performing vortex and centrifugation; taking liquid supernatant; (2) using octadecyl silane bonded silica gel as filling agents for chromatographic column treatment at the column temperature being 40 DEG C, wherein an ultra-high performance liquid chromatography system uses a general binary high-pressure pump and a sample feeding device; using a mixed solution of methanol-ammonium acetate water solution as a flowingphase; performing gradient elution; (3) using an ESI ion source as an ion source and a multi-reaction monitoring mode (MRM) for positive ion detection. The quantitative analysis ions are respectivelyWSJ-557:m / z316.1 to 260.0, m / z237.0 to 194.0; the collision energy is 15eV. The quantitative analysis method has the advantages that the specificity is high; the sensitivity is high; the sampling quantity of samples is small; the pretreatment is simple and fast; the analysis period is short and the like. The method is particularly applicable to the plasma-drug concentration determination and pharmacokinetic study of WSJ-557 in SD rat plasma.

Description

technical field [0001] The invention relates to the field of preclinical pharmacokinetic research of drug analysis, in particular to a method for quantitatively analyzing blood drug concentration of compound WSJ-557 in SD rat plasma. Background technique [0002] Controlling blood uric acid levels plays a key role in the prevention and treatment of gout, but there are few types of xanthine oxidase inhibitors in uric acid-lowering drugs and many side effects. WSJ-557 is a brand-new non-purine xanthine oxidase inhibitor, and its in vitro pharmacodynamic experiments show that the inhibitory activity of WSJ-557 (IC50=0.003μM) is better than febuxostat (IC50 = 0.01 μM) is much higher. Note: IC50 (Half maximal inhibitory concentration) refers to the half inhibitory concentration (or half inhibition rate) of the antagonist being measured. [0003] For the preparation method of compound WSJ-557, please refer to the invention patent with the application date of 2012-08-07, the appl...

AI Technical Summary

Problems solved by technology

[0004] Since WSJ-557 is an innovative drug, there is no literature report on the determination method of its biological samples at home and abroad. In order to be able to carry out animal and human pharmacokinetic studies on its absorption, distribution, metabolism, and excretion in the body, it is necessary to Establishment of a highly sensitive, convenient and rapid quantitative analysis method for WSJ-557 blood drug concentration

Images